Avadel Pharmaceuticals plc [AVDL] stock is trading at $19.24, up 0.47%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AVDL shares have gain 2.83% over the last week, with a monthly amount glided 26.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avadel Pharmaceuticals plc [NASDAQ: AVDL] stock has seen the most recent analyst activity on October 23, 2025, when H.C. Wainwright downgraded its rating to a Neutral but kept the price target unchanged to $20 for it. Previously, Wells Fargo started tracking the stock with Equal Weight rating on September 03, 2025, and set its price target to $16. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $12 on February 11, 2025. Rodman & Renshaw initiated its recommendation with a Buy and recommended $27 as its price target on June 12, 2024. Oppenheimer reiterated a Outperform rating for this stock on March 05, 2024, and upped its price target to $29. In a note dated March 05, 2024, Needham reiterated an Buy rating on this stock and boosted its target price from $20 to $22.
Avadel Pharmaceuticals plc [AVDL] stock has fluctuated between $6.38 and $19.17 over the past year. Currently, Wall Street analysts expect the stock to reach $18.9 within the next 12 months. Avadel Pharmaceuticals plc [NASDAQ: AVDL] shares were valued at $19.24 at the most recent close of the market. An investor can expect a potential drop of -1.77% based on the average AVDL price forecast.
Analyzing the AVDL fundamentals
Avadel Pharmaceuticals plc [NASDAQ:AVDL] reported sales of 248.52M for the trailing twelve months, which represents a growth of 54.86%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.04 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.10 points at the first support level, and at 18.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.32, and for the 2nd resistance point, it is at 19.39.
Ratios To Look Out For
For context, Avadel Pharmaceuticals plc’s Current Ratio is 2.76. In addition, the Quick Ratio stands at 2.37 and the Cash Ratio stands at 1.11. Considering the valuation of this stock, the price to sales ratio is 7.56, the price to book ratio is 19.05.
Transactions by insiders
Recent insider trading involved Palczuk Linda, Director, that happened on Jan 21 ’25 when 5000.0 shares were purchased. Director, Thornton Peter J. completed a deal on Jan 13 ’25 to buy 10000.0 shares. Meanwhile, Director Ende Eric J bought 30000.0 shares on Jan 13 ’25.
